Emerging ECG-Based AI Screening Software for Aortic Valve Stenosis Gets FDA’s Breakthrough Device Designation
With the capability of identifying possible cases of aortic value stenosis (AVS) from existing electrocardiograms (ECGs), the AI-powered screening software from AccurKardia may facilitate earlier diagnosis of AVS, which is fatally missed in 50 percent of patient who have this condition.
The Food and Drug Administration (FDA) has issued its Breakthrough Device Designation for screening software that utilizes artificial intelligence (AI) assessment of existing electrocardiograms (ECGs) to identify patients who may have aortic valve stenosis (AVS).1
Estimated one-year mortality rates can be as high as 50 percent for undetected AVS, according to AccurKardia, the developer of the software.2 However, the company noted the AVS screening software is able to identify patients at risk of AVS through a review of existing ECGs in a patient’s electronic health record. The screening software subsequently flags patients for a follow-up ECG to confirm the AVS diagnosis, according to AccurKardia.
“AccurKardia’s recent advancement has the potential to create a paradigm shift in the detection of aortic valve stenosis, where earlier detection and treatment may mean the difference between life or death,” said Eduardo Hernandez, M.D., president of the Texas Heart Institute Center for Cardiovascular Care in Houston. “Once FDA-cleared and successfully deployed, this technology could become established as a standard-of-care screening tool for AVS in elderly patients.”
Through earlier detection and intervention for AVS, AccurKardia suggests the AI-powered screening software could also reduce heart failure hospitalizations and potentially save millions in health-care costs.
References
1. AccurKardia. AccurKardia receives FDA breakthrough device designation for first-of-its-kind aortic valve stenosis ECG-based AI screening software. Available at: https://www.businesswire.com/news/home/20241008099886/en/AccurKardia-Receives-FDA-Breakthrough-Device-Designation-for-First-of-its-Kind-Aortic-Valve-Stenosis-ECG-based-AI-Screening-Software . Published October 8, 2024. Accessed October 8, 2024.
2. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597-1607.
Recent Videos
Related Content
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Article
Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025Article
The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025Article
The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
